EirGenix Inc. (6589.TWO)

79.70 -0.30 (-0.38%) As of 11:25AM CST. Market open.

EirGenix Inc.

No. 101, Kangning Street
Lane 169 Xizhi District
New Taipei City
Taiwan
886 2 7708 0123
https://www.eirgenix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Lee-Cheng Liu	Founder, President, CEO, CSO & Chairman	10.17M	N/A	N/A
Ms. Hsiu-Chuan Yang	CFO, VP & Manager of Corporate Governance	8.1M	N/A	N/A
Dr. Chih-Jung Chang	VP & COO	7.3M	N/A	N/A
Dr. Thomas Schulze Ph.D.	Managing Director of EirGenix Europe GmbH	N/A	N/A	N/A
Dr. Shang-Chung Ju	Executive Director & Chief Manufacturing Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

Corporate governance

EirGenix Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.